2016 Clinical Trials Programs Treatment 
NORML
APRIL 30, 2020
CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” percent in 2016).” percent in 2016).”
Cannabis Law Report
MAY 10, 2022
Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 10, 2022
Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.
The Cannigma
MAY 19, 2021
Since 2016, the country has permitted the sale of CBD and some Japanese companies produce cannabidiol products as well. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. Shutterstock). Who can get medical cannabis in Japan? Shutterstock).
Cannabis Law Report
SEPTEMBER 1, 2021
The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.
Cannabis Law Report
MAY 29, 2022
Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. Trial of Psilocybin Versus Escitalopram for Depression , 384 New England J.
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. 16, 2016), available at [link]. Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq.
Expert insights. Personalized for you.
345 
Let's personalize your content